Fierce Biotech Mix Logo.png Fierce Biotech Mix Logo.png
Webinar

The Operating Model Shaping Pharma’s Next Decade: How Leading Pharma Companies Are Evolving Their Commercial Operating Model

Available on-demand
60 Minutes

Pharma is entering a period of structural change in how innovation is converted into patient impact. 

Commercial models that were highly effective for decades built around scale, promotion, and late-stage demand creation are now under pressure from forces outside any single organization’s control. 

Standardized testing across health systems, increased payer scrutiny, accelerating patent cliffs, and rising expectations for precision and speed are reshaping how value is created and captured. In this environment, success increasingly depends on how Diagnostics, Data, and Digital execution work together not as individual capabilities, but as a unified commercial operating model. 

Drawing on insights from the D-Cubed Pharma report, this webinar explores how leading biopharma companies are adapting their commercial approach to these realities. We will examine where traditional models begin to show friction, where value can leak between approval and treatment, and how more integrated, diagnostics-led activation models are helping organizations reach eligible patients faster and more efficiently. 

Through real-world examples including diagnostic-triggered engagement, real-time lab intelligence, and precision digital activation speakers will share what is working in practice, what organizations have learned along the way, and how early adopters are scaling these approaches across portfolios. 

Join us to understand what is changing, why it matters now, and how leading organizations are building scalable, future-ready commercial models designed for 2026 and beyond. 

Speakers

0

Peter Keeling

Peter Keeling is the Founder and Board Chair of Diaceutics, guiding the company’s mission to advance precision testing and improve patient outcomes. With over 33 years of experience as a Pharma industry leader, entrepreneur, and strategist, Peter has shaped innovative commercial models and led global teams across therapies, diagnostics, and FMCG. His career began at American Monitor Corporation, overseeing worldwide distribution of diagnostic reagents and equipment. Peter later spent 11 years in senior operational and strategic roles at the Wellcome Foundation, including international sales leadership and global brand responsibility for its antiviral portfolio prior to the merger with Glaxo in 1995. He went on to establish a diagnostics venture before founding Diaceutics in 2005, building it into a global leader supporting biomarker and precision testing programmes for major biopharma companies. Peter holds degrees from Queen’s University Belfast and Buckingham University and was a Visiting Fellow at MIT Sloan. His work in precision medicine includes several peer‑reviewed publications and regular speaking engagements worldwide.

0

Rebecca Fryer

Rebecca Fryer is the Head of Commercial Partnerships at Diaceutics, where she leads the Diaceutics Precision Commercialization Incubator. In this role, Rebecca focuses on advancing and refining the company's precision commercialization strategy and offerings. With a robust background in health and life sciences consulting, she has extensive experience in leading the development of complex corporate strategies and implementing strategic change programs for health providers and biopharma. At Diaceutics, Rebecca works hand in hand with customers to develop insight-led, targeted, and commercially attractive commercialization models. Rebecca is passionate about improving testing, treatment adoption, and ultimately patient outcomes, ensuring that diagnostically enabled therapies reach their full potential.                     

Register here to watch on-demand!